# Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

> **NCT00225121** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 121 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** PF-00299804

## Key facts

- **NCT ID:** NCT00225121
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-11
- **Primary completion:** 2007-04-03
- **Final completion:** 2010-09-23
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2018-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225121, "Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00225121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*